Stephanie Estes, MD

 Stephanie J. Estes, MD is a board certified Obstetrician/Gynecologist and Professor of Reproductive Endocrinology and Infertility at the Penn State Hershey Medical center in Hershey, Pennsylvania.  As a subspecialist, she has a focus on endometriosis and fibroid research and also advances the care of women through advanced reproductive surgery techniques and robotic surgery. 

Q: At what point do you consider medical therapies in your approach to a patient with endometriosis?

Dr. Estes: I consider medical therapies for every patient that I see. There are 3 categories that I think about:

• Are they a candidate for medical therapy?
• Are they a candidate for surgical therapy?
• Lastly, are they a candidate for fertility treatment?

The difference between the plans is if the patient desires fertility. Next, I consider the advantages and disadvantages of medical therapy. The pros of medical therapy are avoiding the risks of surgery, with known and unknown complications or adhesions. And the cons are side effects of medical therapy. Also, medical therapy does not address treating hydrosalpinges, endometriomas, or other deep infiltrating nodules and, clearly, it also inhibits fertility treatment. So, my overall process is looking at the patient’s goal of symptom management and how best to limit their number of surgical procedures. My approach spans many options, and I look at all of those to make an appropriate decision for each patient.

Q: How do you determine what options would be best suited for the patient?

Dr. Estes: The first line of symptom treatment best suited for the patient is always NSAIDs, which are nonsteroidal anti-inflammatory drugs. These are an appropriate first start in managing the dysmenorrhea and pelvic pain that can be associated with endometriosis. If there are no contraindications, the next most common way to manage endometriosis symptoms is combined oral contraceptive pills, transdermal patches, or rings. A key principle, especially when selecting a pill, is to look at the type of estrogen and progestin you’re choosing. Some practitioners may see these pills as equals, but there are differences. I always select a 20-µm ethinyl estradiol pill for my endometriosis patients. Then, I select a progestin, such as norethindrone or levonorgestrel, which provide good suppressive treatment.

The preferred hormonal therapy for endometriosis symptoms not only should be easy for the patient to use but also accomplish management of the symptoms that they are coming in for. Hormonal therapies have a low side-effect profile, which allows the patient to feel well for a long time. We know that endometriosis is a chronic disease, so this is something that the patient is going to need to manage for a long time. I really like to help my patients because they have other things to do in life. They want to take care of their kids, or they’re in school, or have other goals. Patients want to feel well while doing all these activities of life, and so an individualized approach is important. Some of my patients love taking pills, and they are perfectly happy to do so. Other people would prefer a more long-acting treatment so that they do not have to deal with remembering to take a medication every day.

Q: Explain how you would apply the use of an intrauterine device (IUD) to manage endometriosis. 

Dr. Estes: I use many IUDs with progestin because evidence has shown them to be effective in managing endometriosis symptoms, specifically by decreasing dysmenorrhea. I will usually insert them during a patient’s surgery in the operating room. If I identify endometriosis and can place the IUD at the same time of the surgery, this see-and-treat philosophy maximizes the efficiency of patient care—and the patient avoids the discomfort of an in-office insertion. During the patient’s post-operative check, I evaluate how they feel and how the IUD is working for them. I think many patients are candidates for progestin IUDs, especially those who cannot take an estrogen-containing compound.

Q: Where do newly available therapies for endometriosis fit into your overall management approach?

Dr. Estes: Norethindrone 5 mg is an effective treatment for endometriosis and it is US Food and Drug Administration (FDA)‒approved for that cause. And then, the other medications that Penn State Hershey was part of the clinical trials for include Gonadotropin-releasing hormone (GnRH) antagonists such as elagolix. I saw the improvement in symptoms not only in the trial but also in continued follow-up of patients. GnRH antagonists are a group of medications that have a very good side-effect profile. Patients typically do not have significant side effects, however, hot flashes can me common. Hot flashes that can be ameliorated with some add back hormone therapy. The other drugs in the pipeline are relugolix and linzagolix. Relugolix is FDA approved for prostate cancer treatment. Endometriosis trials are expensive, and they are long and hard to do because of the pain factor—people do not want to stop their other medications to do the trial; however, the use of these medications will continue to be studied, and I look further to continuing to fine tune treatment options

Q: Is cost to the patient a consideration during management counseling, and should it be? 

Dr. Estes: Absolutely. It comes up in every conversation because endometriosis is a long-term disease process that needs to be managed throughout the life cycle of a woman; you cannot have something that is going to be so expensive that will have to be taken for years and years or is not going to be continued. Because cost is critical, I use Lupron Depot as well as letrozole, and goserelin implants are also approved for endometriosis treatment. I also occasionally use danazol, which is a very different mechanism of action in select patients, so multiple options are all present. We have streamlined our pre-approval process for the GnRH antagonists to make it fairly easy.

It used to be a little bit harder, but now, if a patient has found that other medications did not offer relief for her endometriosis, then GnRH antagonists are much easier to obtain.

Q: Is there anything else you’d like to add?

Dr. Estes: Our patient involvement in clinical trials is just so valuable for endometriosis disease research. So, anyone out there living with endometriosis who would like to help medical science—wherever you live, wherever you are—get involved because this can help not only you but also the next person who comes after you. We are currently participating in a study right now on quinagolide. It is a vaginal ring that is not hormonal.

Again, we want to keep all options open and see what works and does not work. Science is so fantastic, and it is one of those summary points to note that we always need more information in terms of endometriosis. We really are aspiring to develop and apply treatment options that are effective throughout the lifespan of those affected by endometriosis.

 Stephanie J. Estes, MD is a board certified Obstetrician/Gynecologist and Professor of Reproductive Endocrinology and Infertility at the Penn State Hershey Medical center in Hershey, Pennsylvania.  As a subspecialist, she has a focus on endometriosis and fibroid research and also advances the care of women through advanced reproductive surgery techniques and robotic surgery. 

Q: At what point do you consider medical therapies in your approach to a patient with endometriosis?

Dr. Estes: I consider medical therapies for every patient that I see. There are 3 categories that I think about:

• Are they a candidate for medical therapy?
• Are they a candidate for surgical therapy?
• Lastly, are they a candidate for fertility treatment?

The difference between the plans is if the patient desires fertility. Next, I consider the advantages and disadvantages of medical therapy. The pros of medical therapy are avoiding the risks of surgery, with known and unknown complications or adhesions. And the cons are side effects of medical therapy. Also, medical therapy does not address treating hydrosalpinges, endometriomas, or other deep infiltrating nodules and, clearly, it also inhibits fertility treatment. So, my overall process is looking at the patient’s goal of symptom management and how best to limit their number of surgical procedures. My approach spans many options, and I look at all of those to make an appropriate decision for each patient.

Q: How do you determine what options would be best suited for the patient?

Dr. Estes: The first line of symptom treatment best suited for the patient is always NSAIDs, which are nonsteroidal anti-inflammatory drugs. These are an appropriate first start in managing the dysmenorrhea and pelvic pain that can be associated with endometriosis. If there are no contraindications, the next most common way to manage endometriosis symptoms is combined oral contraceptive pills, transdermal patches, or rings. A key principle, especially when selecting a pill, is to look at the type of estrogen and progestin you’re choosing. Some practitioners may see these pills as equals, but there are differences. I always select a 20-µm ethinyl estradiol pill for my endometriosis patients. Then, I select a progestin, such as norethindrone or levonorgestrel, which provide good suppressive treatment.

The preferred hormonal therapy for endometriosis symptoms not only should be easy for the patient to use but also accomplish management of the symptoms that they are coming in for. Hormonal therapies have a low side-effect profile, which allows the patient to feel well for a long time. We know that endometriosis is a chronic disease, so this is something that the patient is going to need to manage for a long time. I really like to help my patients because they have other things to do in life. They want to take care of their kids, or they’re in school, or have other goals. Patients want to feel well while doing all these activities of life, and so an individualized approach is important. Some of my patients love taking pills, and they are perfectly happy to do so. Other people would prefer a more long-acting treatment so that they do not have to deal with remembering to take a medication every day.

Q: Explain how you would apply the use of an intrauterine device (IUD) to manage endometriosis. 

Dr. Estes: I use many IUDs with progestin because evidence has shown them to be effective in managing endometriosis symptoms, specifically by decreasing dysmenorrhea. I will usually insert them during a patient’s surgery in the operating room. If I identify endometriosis and can place the IUD at the same time of the surgery, this see-and-treat philosophy maximizes the efficiency of patient care—and the patient avoids the discomfort of an in-office insertion. During the patient’s post-operative check, I evaluate how they feel and how the IUD is working for them. I think many patients are candidates for progestin IUDs, especially those who cannot take an estrogen-containing compound.

Q: Where do newly available therapies for endometriosis fit into your overall management approach?

Dr. Estes: Norethindrone 5 mg is an effective treatment for endometriosis and it is US Food and Drug Administration (FDA)‒approved for that cause. And then, the other medications that Penn State Hershey was part of the clinical trials for include Gonadotropin-releasing hormone (GnRH) antagonists such as elagolix. I saw the improvement in symptoms not only in the trial but also in continued follow-up of patients. GnRH antagonists are a group of medications that have a very good side-effect profile. Patients typically do not have significant side effects, however, hot flashes can me common. Hot flashes that can be ameliorated with some add back hormone therapy. The other drugs in the pipeline are relugolix and linzagolix. Relugolix is FDA approved for prostate cancer treatment. Endometriosis trials are expensive, and they are long and hard to do because of the pain factor—people do not want to stop their other medications to do the trial; however, the use of these medications will continue to be studied, and I look further to continuing to fine tune treatment options

Q: Is cost to the patient a consideration during management counseling, and should it be? 

Dr. Estes: Absolutely. It comes up in every conversation because endometriosis is a long-term disease process that needs to be managed throughout the life cycle of a woman; you cannot have something that is going to be so expensive that will have to be taken for years and years or is not going to be continued. Because cost is critical, I use Lupron Depot as well as letrozole, and goserelin implants are also approved for endometriosis treatment. I also occasionally use danazol, which is a very different mechanism of action in select patients, so multiple options are all present. We have streamlined our pre-approval process for the GnRH antagonists to make it fairly easy.

It used to be a little bit harder, but now, if a patient has found that other medications did not offer relief for her endometriosis, then GnRH antagonists are much easier to obtain.

Q: Is there anything else you’d like to add?

Dr. Estes: Our patient involvement in clinical trials is just so valuable for endometriosis disease research. So, anyone out there living with endometriosis who would like to help medical science—wherever you live, wherever you are—get involved because this can help not only you but also the next person who comes after you. We are currently participating in a study right now on quinagolide. It is a vaginal ring that is not hormonal.

Again, we want to keep all options open and see what works and does not work. Science is so fantastic, and it is one of those summary points to note that we always need more information in terms of endometriosis. We really are aspiring to develop and apply treatment options that are effective throughout the lifespan of those affected by endometriosis.

 Stephanie J. Estes, MD is a board certified Obstetrician/Gynecologist and Professor of Reproductive Endocrinology and Infertility at the Penn State Hershey Medical center in Hershey, Pennsylvania.  As a subspecialist, she has a focus on endometriosis and fibroid research and also advances the care of women through advanced reproductive surgery techniques and robotic surgery. 

Q: At what point do you consider medical therapies in your approach to a patient with endometriosis?

Dr. Estes: I consider medical therapies for every patient that I see. There are 3 categories that I think about:

• Are they a candidate for medical therapy?
• Are they a candidate for surgical therapy?
• Lastly, are they a candidate for fertility treatment?

The difference between the plans is if the patient desires fertility. Next, I consider the advantages and disadvantages of medical therapy. The pros of medical therapy are avoiding the risks of surgery, with known and unknown complications or adhesions. And the cons are side effects of medical therapy. Also, medical therapy does not address treating hydrosalpinges, endometriomas, or other deep infiltrating nodules and, clearly, it also inhibits fertility treatment. So, my overall process is looking at the patient’s goal of symptom management and how best to limit their number of surgical procedures. My approach spans many options, and I look at all of those to make an appropriate decision for each patient.

Q: How do you determine what options would be best suited for the patient?

Dr. Estes: The first line of symptom treatment best suited for the patient is always NSAIDs, which are nonsteroidal anti-inflammatory drugs. These are an appropriate first start in managing the dysmenorrhea and pelvic pain that can be associated with endometriosis. If there are no contraindications, the next most common way to manage endometriosis symptoms is combined oral contraceptive pills, transdermal patches, or rings. A key principle, especially when selecting a pill, is to look at the type of estrogen and progestin you’re choosing. Some practitioners may see these pills as equals, but there are differences. I always select a 20-µm ethinyl estradiol pill for my endometriosis patients. Then, I select a progestin, such as norethindrone or levonorgestrel, which provide good suppressive treatment.

The preferred hormonal therapy for endometriosis symptoms not only should be easy for the patient to use but also accomplish management of the symptoms that they are coming in for. Hormonal therapies have a low side-effect profile, which allows the patient to feel well for a long time. We know that endometriosis is a chronic disease, so this is something that the patient is going to need to manage for a long time. I really like to help my patients because they have other things to do in life. They want to take care of their kids, or they’re in school, or have other goals. Patients want to feel well while doing all these activities of life, and so an individualized approach is important. Some of my patients love taking pills, and they are perfectly happy to do so. Other people would prefer a more long-acting treatment so that they do not have to deal with remembering to take a medication every day.

Q: Explain how you would apply the use of an intrauterine device (IUD) to manage endometriosis. 

Dr. Estes: I use many IUDs with progestin because evidence has shown them to be effective in managing endometriosis symptoms, specifically by decreasing dysmenorrhea. I will usually insert them during a patient’s surgery in the operating room. If I identify endometriosis and can place the IUD at the same time of the surgery, this see-and-treat philosophy maximizes the efficiency of patient care—and the patient avoids the discomfort of an in-office insertion. During the patient’s post-operative check, I evaluate how they feel and how the IUD is working for them. I think many patients are candidates for progestin IUDs, especially those who cannot take an estrogen-containing compound.

Q: Where do newly available therapies for endometriosis fit into your overall management approach?

Dr. Estes: Norethindrone 5 mg is an effective treatment for endometriosis and it is US Food and Drug Administration (FDA)‒approved for that cause. And then, the other medications that Penn State Hershey was part of the clinical trials for include Gonadotropin-releasing hormone (GnRH) antagonists such as elagolix. I saw the improvement in symptoms not only in the trial but also in continued follow-up of patients. GnRH antagonists are a group of medications that have a very good side-effect profile. Patients typically do not have significant side effects, however, hot flashes can me common. Hot flashes that can be ameliorated with some add back hormone therapy. The other drugs in the pipeline are relugolix and linzagolix. Relugolix is FDA approved for prostate cancer treatment. Endometriosis trials are expensive, and they are long and hard to do because of the pain factor—people do not want to stop their other medications to do the trial; however, the use of these medications will continue to be studied, and I look further to continuing to fine tune treatment options

Q: Is cost to the patient a consideration during management counseling, and should it be? 

Dr. Estes: Absolutely. It comes up in every conversation because endometriosis is a long-term disease process that needs to be managed throughout the life cycle of a woman; you cannot have something that is going to be so expensive that will have to be taken for years and years or is not going to be continued. Because cost is critical, I use Lupron Depot as well as letrozole, and goserelin implants are also approved for endometriosis treatment. I also occasionally use danazol, which is a very different mechanism of action in select patients, so multiple options are all present. We have streamlined our pre-approval process for the GnRH antagonists to make it fairly easy.

It used to be a little bit harder, but now, if a patient has found that other medications did not offer relief for her endometriosis, then GnRH antagonists are much easier to obtain.

Q: Is there anything else you’d like to add?

Dr. Estes: Our patient involvement in clinical trials is just so valuable for endometriosis disease research. So, anyone out there living with endometriosis who would like to help medical science—wherever you live, wherever you are—get involved because this can help not only you but also the next person who comes after you. We are currently participating in a study right now on quinagolide. It is a vaginal ring that is not hormonal.

Again, we want to keep all options open and see what works and does not work. Science is so fantastic, and it is one of those summary points to note that we always need more information in terms of endometriosis. We really are aspiring to develop and apply treatment options that are effective throughout the lifespan of those affected by endometriosis.